Jazz Pharmaceuticals
JAZZ
406 hedge funds and large institutions have $5B invested in Jazz Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 123 increasing their positions, 171 reducing their positions, and 85 closing their positions.
2.74% less ownership
Funds ownership: 91.96% → 89.22% (-2.7%)
9% less funds holding
Funds holding: 445 → 406 (-39)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
28% less repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 171
33% less call options, than puts
Call options by funds: $18.3M | Put options by funds: $27.2M
39% less capital inflows, than outflows
Capital inflows: $478M | Capital outflows: $777M
45% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 85
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$65.2M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$50.1M |
| 3 |
Sarissa Capital Management
Greenwich,
Connecticut
|
+$41.6M |
| 4 |
Holocene Advisors
New York
|
+$38.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$57.9M |
| 2 |
Bank of New York Mellon
New York
|
-$53.2M |
| 3 |
Wedge Capital Management
Charlotte,
North Carolina
|
-$43.1M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$35.7M |
| 5 |
D.E. Shaw & Co
New York
|
-$33M |
JAZZ Hedge Fund Activity: Q1 2020 in Review
406 of the 4,552 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2020, worth a combined $5B — down 36% from $7.76B a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of JAZZ and 47 opened new positions — a net loss of 38 holders — while 171 trimmed existing stakes and 123 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $65.2M. The largest seller was Arrowstreet Capital, cutting an estimated $57.9M.
- 406 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2020, down from 445 in Q4 2019.
- Funds reported $5B of Jazz Pharmaceuticals stock for Q1 2020, down 36% quarter-over-quarter.
- 47 funds opened new Jazz Pharmaceuticals positions in Q1 2020 and 85 closed out, a net change of -38 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2020 was T. Rowe Price Associates, an estimated $65.2M added.
- The largest Jazz Pharmaceuticals seller in Q1 2020 was Arrowstreet Capital, an estimated $57.9M sold.
Based on aggregated 13F filings for Q1 2020.